These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 29915963)

  • 1. A translational perspective on histone acetylation modulators in psychiatric disorders.
    Ganguly S; Seth S
    Psychopharmacology (Berl); 2018 Jul; 235(7):1867-1873. PubMed ID: 29915963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders.
    Konsoula Z; Barile FA
    J Pharmacol Toxicol Methods; 2012; 66(3):215-20. PubMed ID: 22902970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulating epigenetic HAT activity for reinstating acetylation homeostasis: A promising therapeutic strategy for neurological disorders.
    Ganai SA; Banday S; Farooq Z; Altaf M
    Pharmacol Ther; 2016 Oct; 166():106-22. PubMed ID: 27411674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone Deacetylases as Potential Targets for Cocaine Addiction.
    Kennedy PJ; Harvey E
    CNS Neurol Disord Drug Targets; 2015; 14(6):764-72. PubMed ID: 26022264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
    Hutt DM; Roth DM; Marchal C; Bouchecareilh M
    Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity.
    Fass DM; Reis SA; Ghosh B; Hennig KM; Joseph NF; Zhao WN; Nieland TJ; Guan JS; Kuhnle CE; Tang W; Barker DD; Mazitschek R; Schreiber SL; Tsai LH; Haggarty SJ
    Neuropharmacology; 2013 Jan; 64():81-96. PubMed ID: 22771460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic application of histone deacetylase inhibitors for stroke.
    Lv L; Tang YP; Han X; Wang X; Dong Q
    Cent Nerv Syst Agents Med Chem; 2011 Jun; 11(2):138-49. PubMed ID: 21521169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetate supplementation increases brain histone acetylation and inhibits histone deacetylase activity and expression.
    Soliman ML; Rosenberger TA
    Mol Cell Biochem; 2011 Jun; 352(1-2):173-80. PubMed ID: 21359531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
    Singh AK; Bishayee A; Pandey AK
    Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
    Hanikoglu A; Hanikoglu F; Ozben T
    Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging roles of HDACs and their therapeutic implications in cancer.
    Hai R; Yang D; Zheng F; Wang W; Han X; Bode AM; Luo X
    Eur J Pharmacol; 2022 Sep; 931():175216. PubMed ID: 35988787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
    Li Y; Seto E
    Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone Deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration.
    Ganai SA; Ramadoss M; Mahadevan V
    Curr Neuropharmacol; 2016; 14(1):55-71. PubMed ID: 26487502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylases inhibitors (HDACis) as novel therapeutic application in various clinical diseases.
    Qiu X; Xiao X; Li N; Li Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Jan; 72():60-72. PubMed ID: 27614213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic modulation: Research progress on histone acetylation levels in major depressive disorders.
    Meng Y; Du J; Liu N; Qiang Y; Xiao L; Lan X; Ma L; Yang J; Yu J; Lu G
    J Drug Target; 2023 Feb; 31(2):142-151. PubMed ID: 36112185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone Deacetylase Inhibition via RGFP966 Releases the Brakes on Sensory Cortical Plasticity and the Specificity of Memory Formation.
    Bieszczad KM; Bechay K; Rusche JR; Jacques V; Kudugunti S; Miao W; Weinberger NM; McGaugh JL; Wood MA
    J Neurosci; 2015 Sep; 35(38):13124-32. PubMed ID: 26400942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of histone deacetylases by Trichostatin A leads to a HoxB4-independent increase of hematopoietic progenitor/stem cell frequencies as a result of selective survival.
    Obier N; Uhlemann CF; Müller AM
    Cytotherapy; 2010 Nov; 12(7):899-908. PubMed ID: 20210674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase (HDACs) inhibitors: Clinical applications.
    Shanmukha KD; Paluvai H; Lomada SK; Gokara M; Kalangi SK
    Prog Mol Biol Transl Sci; 2023; 198():119-152. PubMed ID: 37225317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the Expression and Role of Histone Acetylation and Deacetylation in Dental Pulp Cells.
    Yamauchi Y; Duncan HF
    Methods Mol Biol; 2023; 2588():279-293. PubMed ID: 36418694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.